Application of hepcidin antibacterial peptide and engineered extracellular vesicle modified by hepcidin antibacterial peptide in preparation of medicine for treating bone defect

Engineered extracellular vesicles modified with hepcidin antimicrobial peptide expressed on a phospholipid bilayer have solved the problem of poor efficacy of existing bone defect treatments and achieved the effect of promoting bone defect healing.

CN118955730APending Publication Date: 2024-11-15TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410872394.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-01
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing medications for treating bone defects are not very effective, especially in promoting bone defect healing.

Method used

Engineered extracellular vesicles modified with hepcidin antimicrobial peptide (mb Hamp) expressed on a phospholipid bilayer were expressed on the surface of mother cells and collected using gene delivery technology to prepare drugs for treating bone defects.

Benefits of technology

It promotes the differentiation of M0 macrophages into M2 macrophages, promotes osteogenic formation, prevents and treats bone defects, and significantly improves the healing effect of bone defects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955730A_ABST
    Figure CN118955730A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of gene engineering, and discloses application of hepcidin antibacterial peptide and engineered extracellular vesicles modified by the hepcidin antibacterial peptide in preparation of medicine for treating bone defect, mb Hamp is Hamp protein expressed on a phospholipid bimolecular membrane, Hamp is hepcidin antibacterial peptide, and the mb Hamp comprises Hamp and CD8TM connected with the Hamp; the amino acid sequence of the Hamp is as shown in SEQ ID NO: 1, and the amino acid sequence of the CD8TM is as shown in SEQ ID NO: 2. The preparation method of the engineered extracellular vesicle comprises the following steps: enabling a mother cell to express the mb Hamp on the surface of a cell membrane through a gene delivery means, collecting a cell culture supernatant, and carrying out gradient centrifugation to obtain the mb Hamp modified extracellular vesicle, namely the engineered extracellular vesicle disclosed by the invention. The mb Hamp and the engineered extracellular vesicle can be applied to preparation of drugs for treating bone defects.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of gene engineering technology, and in particular relates to the application of hepcidin antimicrobial peptide and engineered extracellular vesicles modified by the peptide in the preparation of drugs for treating bone defects. Background Art

[0002] Hepcidin antimicrobial peptide (Hamp) is a cysteine-rich polypeptide that is mainly synthesized and secreted by the liver. Its amino acid sequence is highly conserved in different species, and various stimuli, such as inflammation, injury, and infection, can strongly cause an increase in its gene expression. When Hamp was first discovered, it was considered to be an antimicrobial peptide and an important component of innate immunity. Subsequent findings have shown that Hamp is also important for adaptive immune responses. Hamp deficiency may cause bone loss by interfering with the Wnt / β-catenin pathway. The main reason is that Hamp deficiency inhibits the differentiation and activity of osteoblasts, but has no effect on the differentiation and activity of osteoclasts.

[0003] Extracellular vesicles are a type of tiny vesicles with a double-layer lipid membrane structure that are released into the surrounding environment by living cells paracrine secretion. They are mainly divided into four categories: exosomes, microvesicles, apoptosis bodies, and oncosomes.

[0004] Bone defect refers to partial bone loss. When the defect is too long, it will lead to non-union of the defect. This is a common clinical disease, and limb bone defects are the most common. There are many factors that directly or indirectly cause bone defects, such as trauma, infection, non-union of bones, bone absorption, innate immune diseases, bone tumor resection, secondary functional damage and other different causes of injury-causing behavioral factors that lead to bone loss.

[0005] Currently, although a variety of different therapeutic drugs have been developed for bone defects, their therapeutic effects are sometimes difficult to be satisfactory. Summary of the invention

[0006] In order to overcome the deficiencies of the above-mentioned prior art, the present invention provides the use of hepcidin antimicrobial peptide and its modified engineered extracellular vesicles in the preparation of drugs for treating bone defects. The present invention discovers a new mechanism of action and indications of Hamp, and creatively designs a Hamp protein (mb Hamp) expressed on a phospholipid bilayer membrane. The engineered extracellular vesicles modified by mb Hamp have the effect of promoting the healing of bone defects and are a new nanomedicine for treating bone defects.

[0007] In order to achieve the above purpose, this application adopts the following technical solutions:

[0008] In a first aspect, the present invention provides a mb Hamp, wherein the mb Hamp is a Hamp protein expressed on a phospholipid bilayer membrane, the Hamp is a hepcidin antimicrobial peptide, and the mb Hamp comprises the Hamp and a CD8 TM connected thereto;

[0009] The amino acid sequence of Hamp is shown in SEQ ID NO: 1, and the amino acid sequence of CD8 TM is shown in SEQ ID NO: 2.

[0010] In the above technical solution, the mb Hamp also includes GFP, the GFP is connected to the CD8 TM, and the amino acid sequence of the GFP is shown in SEQ ID NO:3.

[0011] In a second aspect, the present invention provides an engineered extracellular vesicle, the preparation method of which is: by gene delivery means, the mother cell expresses the mb Hamp described in any one of claims 1-2 on the cell membrane surface, and by collecting the cell culture supernatant and performing gradient centrifugation to obtain the mb Hamp-modified extracellular vesicle, which is the engineered extracellular vesicle.

[0012] In the above technical solutions, the mother cells include but are not limited to human cell lines and human primary cells.

[0013] In the above technical solutions, the gene delivery means include but are not limited to lentiviral transfection and cationic liposome delivery.

[0014] In a third aspect, the present invention provides the use of the above-mentioned mb Hamp and the above-mentioned engineered extracellular vesicles in the preparation of a drug for treating bone defects.

[0015] In the above technical solution, the mb Hamp and engineered extracellular vesicles can promote the differentiation of M0 macrophages into M2 macrophages, promote osteogenesis, and prevent and / or treat bone defects.

[0016] The beneficial effects of the present invention are:

[0017] 1. The present invention has discovered new functions of hepcidin antimicrobial peptide (Hamp), namely: (1) promoting the differentiation of M0 macrophages into M2 macrophages; (2) promoting osteogenesis; and (3) preventing and / or treating bone defects.

[0018] 2. The present invention constructs a membrane-anchored hepcidin antimicrobial peptide structure for modifying phospholipid bilayer structures such as extracellular vesicles.

[0019] 3. The engineered extracellular vesicles EV of the present invention HampEVs can inherit proteins, DNA, and RNA from mother cells. Mother cells used to produce EVs can come from a variety of sources, such as mesenchymal stem cells, which have great development potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 It is a schematic diagram of the structure of the Hamp protein expressed on the phospholipid bilayer membrane of the present invention;

[0021] Figure 2 is a flow chart of the preparation process of the engineered extracellular vesicles of the present invention;

[0022] Figure 3 The engineered extracellular vesicles (EVs) of the present invention Hamp ) and corresponding control factors after intervention of MSCs, the transcription of osteogenic marker genes;

[0023] Figure 4 The engineered extracellular vesicles (EVs) of the present invention Hamp ) and corresponding control factors after intervention of MSCs, the expression of osteogenic differentiation-related proteins;

[0024] Figure 5 yes Figure 4 Semi-quantitative results of grayscale protein blot

[0025] Figure 6 The engineered extracellular vesicles (EVs) of the present invention Hamp ) and the corresponding control factors on the induction of MSCs into osteogenesis;

[0026] Figure 7 The engineered extracellular vesicles (EVs) of the present invention Hamp ) and the corresponding control factors on the M2-type polarization marker genes;

[0027] Figure 8 The engineered extracellular vesicles (EVs) of the present invention Hamp ) and the corresponding control factors on the M1 and M2 polarization marker proteins;

[0028] Fig. 9 yes Figure 8 Semi-quantitative results of grayscale protein blot in the middle;

[0029] Fig.10 It is a package of MSC and EV Hamp Effects of polypeptide hydrogels and corresponding control factors on bone defect healing in rats. DETAILED DESCRIPTION

[0030] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments. The present invention can be implemented in many different forms and should not be construed as being limited to the embodiments set forth herein. On the contrary, these embodiments are provided so that this disclosure will be thorough and complete, and the concept of the present invention will be fully conveyed to those skilled in the art, and the present invention will only be limited by the claims.

[0031] 1. Structure of Hamp protein expressed on phospholipid bilayer membrane

[0032] Its specific structure is as follows Figure 1 As shown in the figure: Hamp is the functional domain of the protein, which plays a biological function; CD8 TM (CD8 transmembrane domain) comes from the transmembrane domain of the CD8 protein, which allows mb Hamp to be expressed on the membrane surface; GFP is a green fluorescent protein, which can be used to quantitatively detect mb Hamp protein in vitro when expressed as a fusion protein with mb Hamp.

[0033] (1) Amino acid sequence of Hamp (SEQ ID NO: 1):

[0034] DTNFPICLFCCKCCKNSSCGLCCITI

[0035] The corresponding non-unique base sequence (SEQ ID NO: 4):

[0036] GATACAAACTTTCCAATCTGCTTATTTTGCTGCAAATGCTGCAAAAATTCTTCTTGCGGCCTCTGCTGTATCACCATT

[0037] Since codons are degenerate, the same amino acid may correspond to multiple codons, so the base sequence listed above is one of the feasible embodiments. In addition, there are other embodiments that are not listed here one by one. The same is true for the following CD8 TM and GFP.

[0038] (2) Amino acid sequence of CD8 TM (CD8 transmembrane domain) (SEQ ID NO: 2):

[0039] WAPLAGICAVLLLSLVITLI

[0040] The corresponding non-unique base sequence (SEQ ID NO: 5):

[0041] TGGGCGCCTTTAGCTGGGATTTGTGCAGTGCTGCTCTTATCTCTTGTGA TCACCCTAATA

[0042] (3) Amino acid sequence of GFP (Green Fluorescent Protein) (SEQ ID NO: 3):

[0043] MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDT LVNRIELKGIDFKEDGNILGHKLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVTAAGITLGMDELYK

[0044] The corresponding non-unique base sequence (SEQ ID NO:6):

[0045] ATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCAC CCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACACCC TGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACCGGCAGCGTGCAGCTC GCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAG

[0046] 2. mb Hamp can be used to deliver genes through lentivirus and other methods to make mother cells express mb Hamp on the cell membrane surface. By collecting the cell culture supernatant and performing gradient centrifugation, engineered extracellular vesicles EV modified with mb Hamp can be collected. Hamp .

[0047] The specific preparation process is as follows Figure 2 As shown, the specific steps are:

[0048] (1) Establishment of mother cell line

[0049] The mother cells may be derived from human cell lines such as HEK-293T, or human primary cells such as mesenchymal stem cells, monocyte macrophages, etc. The gene delivery content includes but is not limited to plasmids and DNA, and the gene delivery method includes but is not limited to lentiviral transfection, cationic liposome delivery, etc.

[0050] Here, the form of lentiviral transfection of HEK-293T is taken as an example. The base sequence described in step 1 above is constructed into a lentiviral vector and infects the HEK-293T cell line. Further, the target protein high expression clone is selected by flow cytometry to establish the HEK-293T mb Hamp Mother cell line.

[0051] (2) Extraction of extracellular vesicles from the supernatant of mother cell culture

[0052] After culturing the mother cells (line) in exosome-free serum medium for 24 hours, the supernatant was aspirated and centrifuged at 1500xrpm, 4C, 5min to separate dead cells and cell debris. The supernatant was used for the next step of centrifugation. 18,000xg 4C, 1h, the precipitate was the extracellular vesicles, which were resuspended in PBS or culture medium without exosomes and stored at -80C.

[0053] 3. Overexpression of Hamp or EV Hamp Can promote bone formation

[0054] (1) Isolation and culture of SD rat bone marrow mesenchymal stem cells (MSCs)

[0055] Take male 60-80g SD rats, euthanize them and soak them in 75% ethanol for 20min. Peel off the skin and muscles of the rats in the clean bench, carefully free the hip and knee joints, obtain complete bilateral femurs and tibias, remove the muscles and fascia on the bone surface, and soak them in sterile PBS for a while. Take out the femur and tibia, cut off both ends of the bones, take a sterile syringe to absorb an appropriate amount of DMEM / F12 complete medium and gently insert the syringe needle from a section of the bone to flush the bone marrow cavity. Repeat the flushing operation until the color of the bone becomes transparent and white. Transfer the flushed culture medium directly to a T25 culture bottle and place it in a 37℃, 5% CO2 cell culture incubator. Replace the culture medium after 48h, and the bottom adherent cells are BMSCs. Thereafter, replace the culture medium every two days. When the cell confluence reaches 80% or more, trypsin digestion and passage can be used. The state and growth rate of MSCs when they are passed to the third generation are suitable for subsequent experiments.

[0056] (2) Osteoblast induction and culture

[0057] MSCs were plated at 5 × 10 4 cells / cm 2The cells were inoculated in a 6-well plate at a density of 1.50 μg / cm2 and cultured in rat bone marrow mesenchymal stem cell osteogenic differentiation medium. Fresh medium was replaced every two days. After 7 days of culture, half of the medium was replaced every two days. After 21 days of culture, the medium was removed and washed twice very gently with PBS. 4% paraformaldehyde was added to cover the cell surface and the cells were fixed for 20 minutes. After fixation, the paraformaldehyde was discarded and the cells were gently washed three times with PBS. Alizarin red dye was added to each well to cover the bottom. After staining for 5 minutes, the dye was discarded. After washing three times with PBS, the cells were placed under a microscope for observation and photography. After osteogenic induction culture, total RNA and protein were extracted for RT-qPCR and Western Blot experiments.

[0058] (3) Overexpression of Hamp or EV Hamp Can promote the expression of osteogenic marker genes and proteins

[0059] Through RT-PCR experiments, we found that Hamp was overexpressed in MSCs. + ) or stimulate MSCs with Hamp-engineered extracellular vesicles (EV Hamp ) can stimulate the expression of osteogenesis-related gene mRNA (ALP, OCN, OPN, Collagen1) Figure 3 ).exist Figure 4-5 Western Blot experiments and their quantitative analysis also confirmed that the expression levels of osteogenic differentiation-related proteins (ALP, Runx2, OPN, Collagen1) were increased in MSCs overexpressing Hamp or stimulated with engineered extracellular vesicles. Figure 6 Alizarin red staining also confirmed the enhanced osteogenic mineralization capacity of MSCs overexpressing Hamp or stimulated with engineered extracellular vesicles.

[0060] 4. EV Hamp Promotes differentiation of M0 macrophages into M2 macrophages

[0061] Mouse macrophage cell line RAW264.7 was cultured at 5×10 4 cells / cm 2 The cells were seeded at a density of 1.54 μg / mL in 6-well plates and cultured in α-MEM medium. Lipopolysaccharide (LPS) was added as a positive control for M1 polarization, and MSCs-conditioned medium was added as a positive control for M2 polarization. Total RNA and protein were extracted 24 hours after stimulation for RT-qPCR and Western Blot experiments.

[0062] After stimulating the macrophage cell line RAW264.7 with Hamp engineered extracellular vesicles, we found that the polarization indicators of macrophages toward M2 (Arg1, IL10) were significantly increased by RT-qPCR experiments ( Figure 7 Western blot experiments also showed that after Hamp engineered extracellular vesicles stimulated macrophages, the expression of M2 marker proteins (CD206, Arg1) increased, while the expression of M1 marker proteins (iNOS, CD86) did not change significantly. Fig. 9 for Figure 8 Grayscale quantitative results.

[0063] 5. EV Hamp Promote bone defect repair

[0064] Eight-week-old SD rats were anesthetized with sodium pentobarbital, and the right leg was shaved and placed on a sterile operating table. After disinfection, the skin was cut with a sharp knife, and the subcutaneous tissue was bluntly separated until the femur. After the femur was fixed, a drill with a diameter of 3 mm was used to drill a hole near the femoral condyle, and the drilling depth was about 5 mm. The control group was given simple polypeptide hydrogel filling treatment; experimental group 1 was given polypeptide hydrogel filling treatment encapsulating MSC and EVNC; experimental group 2 was given polypeptide hydrogel encapsulating MSC and EVNC Hamp After surgery, the muscles, fascia, and skin were sutured in layers, and the mice were returned to the cage after disinfection. They were given sufficient food and water and kept in a comfortable environment for 4 weeks to observe the bone defect repair.

[0065] Depend on Fig.10 It can be seen that the healing and repair of bone defects were examined by micro-CT. After the femoral defects of SD rats were treated with polypeptide hydrogels encapsulating MSCs and EVNCs, the defect healing and repair of the experimental group was better than that of the control group, the defect area was significantly reduced, the bone growth was good, and the MSCs and EVNCs were encapsulated at the same time. Hamp The healing effect of the polypeptide hydrogel (experimental group 2) was better than that of the polypeptide hydrogel encapsulating MSC and EVNC (experimental group 1). This experiment showed that Hamp-engineered extracellular vesicles can promote the repair of femoral defects in SD rats.

[0066] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.

Claims

1. A mb Hamp, wherein the mb Hamp is a Hamp protein expressed on a phospholipid bilayer membrane, and the Hamp is a hepcidin antimicrobial peptide, characterized in that: The mb Hamp includes Hamp and CD8 TM connected thereto; The amino acid sequence of the Hamp is shown in SEQ ID NO: 1, and the amino acid sequence of the CD8 TM is shown in SEQ ID NO:

2.

2. The mb Hamp of claim 1, wherein: The mb Hamp also includes GFP, which is connected to the CD8 TM. The amino acid sequence of the GFP is shown in SEQ ID NO:

3.

3. An engineered extracellular vesicle, characterized in that: The preparation method is as follows: by gene delivery means, the mother cell expresses the mb Hamp described in any one of claims 1-2 on the cell membrane surface, and by collecting the cell culture supernatant and performing gradient centrifugation, the mb Hamp-modified extracellular vesicles are obtained, namely the engineered extracellular vesicles.

4. The engineered extracellular vesicle according to claim 3, characterized in that: The parent cells include, but are not limited to, human cell lines and human primary cells.

5. The engineered extracellular vesicle according to claim 3, characterized in that: The gene delivery means include but are not limited to lentiviral transfection and cationic liposome delivery.

6. Use of the mb Hamp according to any one of claims 1 to 2 and the engineered extracellular vesicles according to any one of claims 3 to 5 in the preparation of a drug for treating bone defects.

7. The use according to claim 6, characterized in that: The mb Hamp and engineered extracellular vesicles can promote the differentiation of M0 macrophages into M2 macrophages, promote osteogenesis, and prevent and / or treat bone defects.